Equities analysts expect Novartis AG (NYSE:NVS) to report earnings of $1.29 per share for the current quarter, according to Zacks. Zero analysts have made estimates for Novartis’ earnings. The lowest EPS estimate is $1.28 and the highest is $1.30. Novartis reported earnings of $1.28 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 0.8%. The firm is scheduled to announce its next quarterly earnings results on Thursday, April 18th.
On average, analysts expect that Novartis will report full year earnings of $5.42 per share for the current year, with EPS estimates ranging from $5.22 to $5.60. For the next year, analysts expect that the business will post earnings of $6.01 per share, with EPS estimates ranging from $5.73 to $6.25. Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Novartis.
Get Novartis alerts:Novartis (NYSE:NVS) last released its quarterly earnings results on Wednesday, January 30th. The company reported $1.24 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.33 by ($0.09). Novartis had a net margin of 24.30% and a return on equity of 15.66%. The firm had revenue of $13.27 billion for the quarter, compared to the consensus estimate of $13.33 billion. During the same quarter in the prior year, the firm earned $1.21 earnings per share. The company’s revenue for the quarter was up 2.7% compared to the same quarter last year.
Several equities research analysts recently weighed in on the company. Cowen upgraded Novartis from a “market perform” rating to an “outperform” rating and set a $88.03 price target on the stock in a research report on Sunday, December 2nd. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novartis in a research report on Wednesday, November 28th. Jefferies Financial Group restated a “buy” rating and set a $105.00 price target on shares of Novartis in a research report on Tuesday, December 11th. Goldman Sachs Group upgraded Novartis from a “neutral” rating to a “conviction-buy” rating in a research report on Friday, November 16th. Finally, Barclays lowered Novartis from an “equal weight” rating to a “sell” rating in a research report on Friday, December 7th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $90.94.
Institutional investors have recently added to or reduced their stakes in the business. Naples Global Advisors LLC lifted its holdings in shares of Novartis by 0.6% during the fourth quarter. Naples Global Advisors LLC now owns 20,599 shares of the company’s stock valued at $1,815,000 after purchasing an additional 115 shares in the last quarter. Camelot Portfolios LLC increased its holdings in Novartis by 1.2% in the fourth quarter. Camelot Portfolios LLC now owns 10,063 shares of the company’s stock valued at $863,000 after buying an additional 123 shares during the last quarter. Financial Architects Inc increased its holdings in Novartis by 0.8% in the fourth quarter. Financial Architects Inc now owns 15,015 shares of the company’s stock valued at $1,288,000 after buying an additional 125 shares during the last quarter. Proficio Capital Partners LLC boosted its stake in Novartis by 3.8% in the fourth quarter. Proficio Capital Partners LLC now owns 3,511 shares of the company’s stock valued at $301,000 after acquiring an additional 129 shares in the last quarter. Finally, Stephens Inc. AR boosted its stake in Novartis by 0.6% in the fourth quarter. Stephens Inc. AR now owns 22,656 shares of the company’s stock valued at $1,944,000 after acquiring an additional 141 shares in the last quarter. 11.56% of the stock is currently owned by institutional investors and hedge funds.
Shares of NYSE NVS traded down $0.38 during mid-day trading on Thursday, hitting $89.43. 1,672,800 shares of the stock traded hands, compared to its average volume of 2,050,518. The company has a quick ratio of 0.97, a current ratio of 1.20 and a debt-to-equity ratio of 0.29. Novartis has a 52 week low of $72.30 and a 52 week high of $92.39. The firm has a market capitalization of $209.70 billion, a PE ratio of 17.57, a P/E/G ratio of 1.97 and a beta of 0.69.
The company also recently declared an annual dividend, which will be paid on Wednesday, March 13th. Investors of record on Tuesday, March 5th will be given a dividend of $2.8646 per share. The ex-dividend date of this dividend is Monday, March 4th. This is a positive change from Novartis’s previous annual dividend of $2.33. This represents a dividend yield of 3.27%. Novartis’s payout ratio is currently 37.52%.
Novartis Company Profile
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
Read More: Quiet Period Expirations Explained
Get a free copy of the Zacks research report on Novartis (NVS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments :
Post a Comment